Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

The relationship between headache and hypertension has been debated for ... Survey of Adults (subsequently known as NHANES), [1] which was first conducted in 1960-1962, when effective ...

Being rushed to a hospital nearly two hours away, in the middle of a dangerous spring storm – with fear in her heart and ...

The Indian equity markets extended their losing streak for the sixth straight session on Thursday. The Sensex fell by 110.64 ...

Georgia was graded an F in the 2024 March of Dimes Report Card for its high rate of preterm births, according to the March of Dimes. The preterm birth rate in Georgia was 11.8% in 2023, higher than ...

We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future." ...

0.97-1.35). However, ICI-ICI therapy was associated with a significantly lower risk of hypertension than VEGF TKI therapy alone (OR, 0.03; 95% CI, 0.02-0.06). There were 16 grade 5 adverse events ...

In metastatic NSCLC resistant to previous PD-1/L1 therapy1 ... 46.7% of patients experienced grade 3 or higher treatment-related adverse effects. Most common AE is myelosuppression, GI side effect, ...

Physical function assessments with TUG and SPPB did not identify a decline in function among patients with CRPC receiving darolutamide over 24 weeks.

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...